A new benchmarking survey of 33 biotech and medtech leaders reveals a leadership community operating in crisis mode — and what that means for how the industry needs to rethink peer support, advisory and the isolation built intothe CEO role itself.
Ken Banta
Advertisement
Founder and CEO of The Vanguard Network, a membership organization that supports and advises CEOs and their senior teams. Banta is former head of strategic affairs at Schering-Plough, Bausch & Lomb, and Pharmacia and helped lead 11 global turnarounds, mergers, and transformations. He began his career as a correspondent/writer with Time Magazine, including as Eastern Europe bureau chief covering the fall of communism and the democratic revolutions of the region.
Banta is the author of “Seeing Around Corners”: C-Suite wisdom from America’s most insightful leaders.
Articles by Ken Banta
Ken Banta and Craig Tooman on why the best leaders win by asking better questions — not just chasing more data — and what that means for drug development, funding and AI in the years ahead.
Ken Banta and Andy Milligan explore how life sciences leaders can rebuild relevance, consistency, and trust in today's complex and cost-focused era of healthcare.
Ken Banta and Andrew Hall share insights on leading through uncertainty—covering culture, capital, risk, and the regulatory headwinds influencing key decisions in drug development.
A case study in leading and guiding a cultural reset and strategic revival.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
Pharmaceutical Executive Daily: FDA Approves Fayuvi
3
The Battle to Own the GLP-1 Patient Journey
4
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
5